Nachrichten zur ASTELLAS PHARMA INC. Aktie

Iveric Bio Stock Surges. Its Being Bought by Astellas for $5.9 Billion.

Japan's Astellas agrees to pay $40 a share for Iveric, citing the potential of the biopharmaceutical company's ophthalmology programs....…

Iveric Bio Shares Rise Premarket on Takeover by Astellas >ISEE

Iveric Bio Shares Rise Premarket on Takeover by Astellas >ISEE...…

First Republic, JPMorgan, Iveric Bio, Apple, and More Stock Market Movers

JPMorgan Chase is acquiring all the deposits and 'substantially all of the assets' of regional lender First Republic Bank, the…

Astellas to acquire IVERIC Bio for $5.9B

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Astellas to buy Iveric Bio for $5.9 billion to expand eyesight treatments

The deal marks the fifth major overseas acquisition by Astellas, Japans third biggest drugmaker by sales, since 2019....…

Astellas Pharma to acquire Iveric Bio in USD5.9 billion deal

Um den gesamten Artikel unter morningstar.co.uk zu lesen, klicken Sie bitte auf die Überschrift...…

Astellas Pharma agrees to buy Iveric Bio for $5.9 Billion

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Astellas Pharma To Acquire Iveric Bio In $5.9 Bln Deal

TOKYO (dpa-AFX) - Astellas Pharma Inc. (ALPMY, ALPMY) agreed to acquire Iveric bio Inc. (ISEE) for US$40.00 per share in…

Astellas Pharma: To Buy Iveric Bio for About $5.9B >4503.TO >4503.TO ISEE

Astellas Pharma: To Buy Iveric Bio for About $5.9B >4503.TO >4503.TO ISEE...…

Astellas Pharma to Buy Iveric Bio for $5.9 Billion

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...…

Astellas Pharma buys Iveric Bio for $5.9 billion

...(Reuters) - Japans Astellas Pharma said on Monday it had fully......…

Astellas Pharma buys Iveric Bio for $5.9 bln

...May 1 (Reuters) - Japans Astellas Pharma said on Monday it had fully......…

Astellas Enters into Definitive Agreement to Acquire Iveric Bio

-Companies to Create World-Class Ophthalmology Entity- -Lead Program, Avacincaptad Pegol for the Potential Treatment of Geographic Atrophy with PDUFA Goal…

Chinese Ambassador Says Astellas Pharma Incident Involved Spying

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...…

Astellas Pharma reports FY results

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Astellas Pharma Annual Profit Declines, But Revenue Increases

TOKYO (dpa-AFX) - Astellas Pharma Inc. (ALPMY) Thursday reported profit before tax of 132.361 billion yen for the fiscal year…

Watch Japan Ahead: Astellas Pharma CEO

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...…

Astellas, CiRA, advance research on medical use of iPS cells

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Spying by Astellas Employee Becoming Clear: China Envoy

Beijing, April 8 (Jiji Press)--Chinese Ambassador to Japan Wu Jianghao has said that espionage allegations against a Japanese employee of…

UPDATE 1-Japan embassy staff in Beijing met detained Astellas Pharma businessman 

...(Updates throughout) TOKYO, April 4 (Reuters) - Japanese embassy......…

Japan Consul Meets Astellas Employee Detained in China

Beijing, April 4 (Jiji Press)--A Japanese consul had a meeting on Tuesday with a Japanese employee of drugmaker Astellas Pharma…

Keidanren Chief Urges China to Release Astellas Employee

Tokyo, April 4 (Jiji Press)--Masakazu Tokura, chairman of the Japan Business Federation, or Keidanren, said Tuesday that he has told…

Entrada Therapeutics Appoints Dr. Bernhardt Zeiher to its Board of Directors

BOSTON, April 04, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform…

Japan PM strongly demands Beijing release detained Astellas employee

...TOKYO (Reuters) - Japans Prime Minister Fumio Kishida said......…

Astellas, Roche To Develop Integrated Diabetes Self-management Solution With BlueStar

SOUTH SAN FRANCISCO (dpa-AFX) - Astellas Pharma Inc. said that it has reached an agreement with Roche Diabetes Care Japan…

China Detains Japanese Employee From Drugmaker Astellas

The arrest on suspicion of spying comes as Beijing seeks to reassure foreign executives that it is open for business,…

China Detains Employee of Japanese Drugmaker Astellas

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...…

UPDATE 1-Japanese man detained in China is Astellas Pharma employee

...(Updates with confirmation by Astellas) TOKYO, March 26 (Reuters..., a company spokesperson told Reuters on Sunday. The company did......…

Japanese man detained in China is Astellas Pharma employee - Kyodo

...TOKYO, March 26 (Reuters) - A Japanese man detained in China.... Reuters was not able to reach a spokesperson for the Japanese company......…

UPDATE 1-US declines to force lower price on cancer drug Xtandi

... (Reuters) - The U.S. government will not force Pfizer Inc and Astellas......…

Pfizer and Astellas avoid forced price reduction for cancer therapy Xtandi

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Pfizer, Astellas Tout Positive Xtandi Data To Potentially Expand Label For The Prostate Cancer Drug

read more...…

Astellas: Phase 3 Study Of Xtandi In Metastatic Hormone-sensitive Prostate Cancer Meets Main Goal

TOKYO (dpa-AFX) - Astellas Pharma Inc. (ALPMY) announced positive results from the Phase 3 China ARCHES study of Xtandi (enzalutamide)…

Astellas Says Phase 3 MORPHO Study Of Gilteritinib Did Not Meet Its Main Goal

TOKYO (dpa-AFX) - Astellas Pharma Inc. (ALPMY) and the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Thursday said…

Astellas Announces Update on Preliminary Safety and Efficacy Data from FORTIS Study of Investigational AT845 in Adults with Late-Onset Pompe Disease

Data presented at the 19th Annual WORLDSymposium™ 2023 TOKYO, Feb. 22, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President…

FDA extends review period of Astellas fezolinetant to treat menopause symptoms

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Astellas Provides Update on Fezolinetant New Drug Application in U.S.

TOKYO, Feb. 19, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced…

Astellas Commits to Achieve Net Zero Greenhouse Gas Emissions by 2050

TOKYO, Feb. 9, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced…

Astellas Pharma GAAP EPS of ¥103.61, revenue of ¥1.17B

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Astellas Pharma announces management changes

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Astellas Pharma Board Approves Changes Of Management Structure

TOKYO (dpa-AFX) - Astellas Pharma Inc. (ALPMY, ALPMY) announced that its board approved changes of its Representative Director, President and…

Astellas Announces Change of President and CEO and Management Structure

TOKYO, Feb. 5, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced…

CytomX stock rises as Astellas to pay $5M milestone under research pact

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

CytomX Therapeutics Announces Milestone Achievement in Probody® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

-Achievement of clinical candidate is the first in the multi-target collaboration and triggers a $5 million milestone payment to CytomX-...…

Sandoz To Acquire Antifungal Agent Mycamine From Astellas Pharma

BASEL (dpa-AFX) - Sandoz said it has entered into an agreement to acquire worldwide product rights for systemic antifungal agent…

Astellas Transfers MYCAMINE® Product Worldwide

TOKYO, Jan. 23, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced…

Sandoz announces agreement to acquire leading antifungal agent Mycamine® from Astellas, reinforcing hospital offering and leading Anti-Infectives portfolio

Basel, January 24, 2023 – Sandoz, the global leader in off-patent (generic and biosimilar) medicines, has signed an agreement to…

Astellas Pharma: FDA Lifts Clinical Hold On Trial Of AT845 In Late-Onset Pompe Disease

TOKYO (dpa-AFX) - Astellas Pharma Inc. (ALPMY, ALPMY) said Friday that the U.S. Food and Drug Administration has lifted the…

Astellas Announces Hold Lifted by FDA on FORTIS Clinical Trial of AT845 Investigational Treatment for Adult Patients with Late-Onset Pompe Disease

TOKYO, Jan. 20, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced…

Leap rebounds as Astellas posts Phase 3 data for rival cancer candidate

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…